Publications by authors named "Ke-da Yu"

Claim this Profile
P
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
Lei Fan, Wen-Juan Zhang, Hui-Ping Li, Xiao-Hua Zeng, Yue-E Teng, Yue Gong, De-Yuan Fu, Bao-Hua Yu, Yun Wang, Xi-Yu Liu, Ke-Da Yu, Guang-Yu Liu, Yu Shen

Cancer Cell· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
Xi-Yu Liu, Xin-Yi Sui, Ying Xu, Fan Yang, Song-Yang Wu, Guang-Yu Liu, Ke-Da Yu

Mol Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.
Yin Liu, Yue Gong, Xiu-Zhi Zhu, Guang-Yu Liu, Ke-Da Yu

BMJ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer.
Li Chen, Shu-Hao Jiang, Guang-Yu Liu, Ke-Da Yu, Jiong Wu, Yu Shen

Mol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Y-chromosome microdeletion screening in Chinese male infertility patients: a large-scale multi-centre study on incidence.
Wei-Kang Chen, Zu-Bo Liu, Tong-Tong Lin, Yuan-Yuan Zhou, Le-Jun Li, Ke-Da Yu

Hum Reprod· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study.
Li Chen, Wen-Ya Wu, Fei Liang, Guang-Yu Liu, Ke-Da Yu

Cancer Commun (Lond)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond.
You-Peng Ding, Cui-Cui Liu, Ke-Da Yu

Exp Hematol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer.
Yu-Fei Chen, Qing-Hua Zhang, Zhong-Wei Zhang, Yu-Jie Zhou, Cui-Cui Liu, Ke-Da Yu

Proc Natl Acad Sci U S A· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review.
Rui-Chen Xu, Yan-Wu Zhang, Cui-Cui Liu, Ying-Ying Xu, Zhi-Ming Shao, Ke-Da Yu

Lancet Reg Health West Pac· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial intelligence-based diagnosis of breast cancer by mammography microcalcification.
Qing Lin, Wei-Min Tan, Jing-Yu Ge, Yan Huang, Qin Xiao, Ke-Da Yu

Fundam Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer: pathogenesis and treatments.
Xin Xiong, Le-Wei Zheng, Yu Ding, Yu-Fei Chen, Yu-Wen Cai, Ke-Da Yu

Signal Transduct Target Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling the peripheral nervous System's role in tumor: A Double-edged Sword.
Yan-Hao Wang, Xuan Yang, Cui-Cui Liu, Xin Wang, Ke-Da Yu

Cancer Lett· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.
Yu-Wen Cai, Cui-Cui Liu, Yan-Wu Zhang, Yi-Ming Liu, Lie Chen, Ke-Da Yu

J Clin Invest· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
Min He, Yi-Zhou Jiang, Yue Gong, Lei Fan, Xi-Yu Liu, Guang-Yu Liu, Ke-Da Yu, De-Yuan Fu

BMJ· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering breast cancer dynamics: insights from single-cell and spatial profiling in the multi-omics era.
Xin Xiong, Xin Wang, Cui-Cui Liu, Zhi-Ming Shao, Ke-Da Yu

Biomark Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study.
Min He, Shuang Hao, LinXiaoxi Ma, BingQiu Xiu, BenLong Yang, YaYun Chi, XiYu Liu, GuangYu Liu, KeDa Yu

EClinicalMedicine· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Lei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, Song-Yang Wu, Jiong Wu, Ke-Da Yu, Xi-Yu Liu, Yun-Song Yang, Guang-Yu Liu

Lancet Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer.
Cui-Cui Liu, Lie Chen, Yu-Wen Cai, Yu-Fei Chen, Yi-Ming Liu, Yu-Jie Zhou, Ke-Da Yu

Cell Rep Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial.
Wen-Jia Zuo, Li Chen, Yu Shen, Zhong-Hua Wang, Guang-Yu Liu, Ke-Da Yu

Ther Adv Med Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase separations in oncogenesis, tumor progressions and metastasis: a glance from hallmarks of cancer.
Le-Wei Zheng, Cui-Cui Liu, Ke-Da Yu

J Hematol Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects.
Lie Chen, Cui-Cui Liu, Si-Yuan Zhu, Jing-Yu Ge, Yu-Fei Chen, Ke-Da Yu

JCI Insight· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inconsistent Data Between Distant Relapse Events and Breast Cancer-Specific Death Events in India Lidocaine Trial.
Ke-Da Yu

J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu, Ke-Da Yu, Guang-Yu Liu, Xiao-Yu Zhu

Cell Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant mannose-sensitive hemagglutinin (PA-MSHA) and chemotherapy versus placebo plus chemotherapy in patients with HER2-negative breast cancer: a randomized, controlled, double-blind trial.
Yue Gong, Hua Zuo, Ying Zhou, Ke-Da Yu, Guang-Yu Liu

Ann Transl Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Single-Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination.
Yi-Ming Liu, Jing-Yu Ge, Yu-Fei Chen, Tong Liu, Lie Chen, Yi-Yu Chen, Yu-Wen Cai, Ke-Da Yu

Adv Sci (Weinh)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis